Long‐term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis
- 1 February 1995
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 4 (1) , 35-40
- https://doi.org/10.1111/j.1468-3083.1995.tb00281.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effects of Monomethylfumarate on Human GranulocytesJournal of Investigative Dermatology, 1993
- Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatmentJournal of the American Academy of Dermatology, 1992
- Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled studyJournal of the American Academy of Dermatology, 1990
- Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid EsterDermatology, 1990
- Akutes Nierenversagen unter Psoriasistherapie mit FumarsäurederivatenDeutsche Medizinische Wochenschrift (1946), 1990
- Nephrotoxische Wirkung einer Therapie mit Fumarsäureestern bei Psoriasis*Deutsche Medizinische Wochenschrift (1946), 1990
- Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasisJournal of the American Academy of Dermatology, 1989
- Der einfluß von fumarsäuremonoäthylester auf die nucleinsäure- und proteinsynthese PHA-stimulierter menschlicher lymphocytenArchives of Dermatological Research, 1975